Babjuk M. Re: Durvalumab in Combination with BCG for BCG-naive, High risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 Trial. Eur Urol 2026 Feb 3:S0302-2838(26)00027-8. doi: 10.1016/j.eururo.2026.
PMID: 41638957